Skip to main content
. 2018 May 17;3(10):e120365. doi: 10.1172/jci.insight.120365

Figure 1. Effect of PBI-4050 treatment on albuminuria and glomerular filtration rate (GFR).

Figure 1

(A) PBI-4050 treatment prevented the gradual increase in albuminuria seen in vehicle-treated eNOS–/– db/db mice from 8–20 weeks of age. **P < 0.01 vs. corresponding vehicle group at the same time point; n = 12 in vehicle group and n = 10 in PBI-4050. (B) From 8–20 weeks of age, GFR markedly decreased in vehicle-treated eNOS–/– db/db mice but was stable in PBI-4050–treated eNOS–/– db/db mice, with higher GFR in PBI-4050 group than in vehicle group at 20 weeks of age. **P < 0.01 vs. baseline; †P < 0.05 vs. vehicle group at 20 weeks of age; n = 10 in baseline group, n = 6 in vehicle group, n = 9 in PBI-4050 group. All values are shown as mean ± SEM. P values were calculated by Student’s t test in A and by ANOVA and Bonferroni’s t test in B.